ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
Alumis Inc. (ALMS) shares dropped 57% after its Phase 2b lupus study missed primary goals, though a patient subgroup showed promising results. The company plans to discuss a late-stage trial with regulators. Wells Fargo and Baird lowered price targets but maintained positive ratings. ALMS is down 3% year-to-date.
How this was made
The 30-second read
Why it matters
The failed Phase 2b readout sharply reduces near‑term valuation, but subgroup signals keep longer‑term interest alive.
Market read
The trial miss drives a steep sell‑off, highlighting the sensitivity of biotech stocks to clinical data.
What to watch
Potential upside from a focused Phase 3 lupus study and a separate psoriasis approval path.
Background
Alumis Inc. is a clinical‑stage biotech developing envudeucitinib for autoimmune diseases.
Ticker impact
Phase 2b lupus trial missed primary and key secondary endpoints, causing a 57% share collapse.
Further downside pressure; potential short‑sell opportunities.
First disclosure of trial failure with a large intraday move; market reaction already severe.
Market effects
Biotech sector may see broader risk aversion as trial failures raise concerns about lupus pipeline.
US biotech stocks could face heightened volatility.
Limited to investors tracking clinical‑trial outcomes.
Counterpoint
Some investors may view the drop as overreaction given the promising subgroup data and upcoming psoriasis filing.
Key entities
- companyAlumis Inc.
Biotech developing envudeucitinib.
- analystWells Fargo
Reduced price target to $25.
- analystBaird
Reduced price target to $27.
